WO2018100581A9 - Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline - Google Patents

Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline Download PDF

Info

Publication number
WO2018100581A9
WO2018100581A9 PCT/IL2017/051307 IL2017051307W WO2018100581A9 WO 2018100581 A9 WO2018100581 A9 WO 2018100581A9 IL 2017051307 W IL2017051307 W IL 2017051307W WO 2018100581 A9 WO2018100581 A9 WO 2018100581A9
Authority
WO
WIPO (PCT)
Prior art keywords
compound
diabetes mellitus
insulin resistance
mellitus type
type
Prior art date
Application number
PCT/IL2017/051307
Other languages
English (en)
Other versions
WO2018100581A2 (fr
Inventor
Joseph Hillel
Gil Atzmon
Dov GEFEL
Rony KALMAN
Ehud Ziv
Colin BAXTER JONES
Lior WAYN
Oren MAIMONI
Original Assignee
Mir2Me Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mir2Me Ltd. filed Critical Mir2Me Ltd.
Publication of WO2018100581A2 publication Critical patent/WO2018100581A2/fr
Publication of WO2018100581A9 publication Critical patent/WO2018100581A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/IL2017/051307 2016-12-01 2017-11-30 Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline WO2018100581A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL249355A IL249355B (en) 2016-12-01 2016-12-01 A compound for the treatment of type 2 diabetes and insulin resistance
IL249355 2016-12-01

Publications (2)

Publication Number Publication Date
WO2018100581A2 WO2018100581A2 (fr) 2018-06-07
WO2018100581A9 true WO2018100581A9 (fr) 2018-07-26

Family

ID=58669510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2017/051307 WO2018100581A2 (fr) 2016-12-01 2017-11-30 Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline

Country Status (2)

Country Link
IL (1) IL249355B (fr)
WO (1) WO2018100581A2 (fr)

Also Published As

Publication number Publication date
IL249355B (en) 2018-05-31
WO2018100581A2 (fr) 2018-06-07
IL249355A0 (en) 2017-04-02

Similar Documents

Publication Publication Date Title
EP3781147A4 (fr) Insuline sensible au glucose
EP3587399A4 (fr) Composé, matériau électroluminescent et élément électroluminescent
EP3148571A4 (fr) Composition utilisable en vue du traitement du diabète sucré et contenant de l'insuline et un double agoniste du glp-1/glucagon
EP3385255A4 (fr) Composé fongicide, composition fongicide, leur préparation et leur utilisation
EP3268448A4 (fr) Composé électrochromique, composition électrochromique, élément électrochromique et élément d'obscurcissement électrochromique
EP3112439A4 (fr) Substance luminescente, élément organique luminescent et composé associé
EP3310877A4 (fr) Composé électrochromique, composition électrochromique et élément d'affichage électrochromique
EP3448417A4 (fr) Conjugués dimères d'insuline-incrétine
EP3246326A4 (fr) Composé, mélange le comprenant, composition et dispositif électronique organique
EP3506964A4 (fr) Seringue contraignante
EP3538141A4 (fr) Ligand ilt3
EP3561023A4 (fr) Matériau luminescent, composé et élément luminescent organique
EP4086280A4 (fr) Dérivé d'insuline
EP3341404A4 (fr) Nouveaux analogues d'insuline et leur utilisation
EP3155017A4 (fr) Produits pharmaceutiques peptidiques améliorés contre l'insulinorésistance
EP3458457A4 (fr) Composé organique électroluminescent, matériau organique électroluminescent et dispositif organique électroluminescent les comprenant
EP3122183A4 (fr) Composition herbicide, procédé pour sa préparation et son utilisation
EP3511321A4 (fr) Élément électroluminescent organique, et matériau électroluminescent et composé destiné à être utilisé dans celui-ci
EP3137572A4 (fr) Composé électrochromique, composition électrochromique, élément d'affichage et élément d'obscurcissement
EP3542777A4 (fr) Composition médicinale pour canal radiculaire
EP3280450A4 (fr) Conjugués d'insuline sensibles au glucose
EP3820549A4 (fr) Ensemble seringue
EP3746155A4 (fr) Ensemble seringue
EP3197869A4 (fr) Composé organique électroluminescent, et matériau organique électroluminescent et dispositif organique électroluminescent le comprenant
HK1244216A1 (zh) 治療2型糖尿病患者

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17876375

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM X1205A DATED 09/10/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17876375

Country of ref document: EP

Kind code of ref document: A2